← All indications
Emphysema
A pathological accumulation of air in tissues or organs.
Subtype terms (3)
More specific conditions that are subtypes of Emphysema in the MeSH hierarchy.
Drugs by status
Approved for this indication (14)
Phase 4 trials (7)
Phase 3 trials (3)
Phase 2 trials (13)
Phase 1 trials (7)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (19)
- CSL Behring
- Shire
- AstraZeneca
- Merck
- Chiesi
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pittsburgh
- Cairo University
- Katholieke Universiteit Leuven
- Johns Hopkins University
- University of East Anglia
- University of Iowa
- University of British Columbia
- University of California, Los Angeles
- Leiden University
- University of Amsterdam
- University of Sao Paulo
- Noordwest Ziekenhuisgroep
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (29)
- Roche
- Pfizer
- Aeris Therapeutics
- Mereo BioPharma
- Otsuka
- Gerard Turino
- University of Pennsylvania
- University of Florida
- University of Miami
- University of Nebraska
- University of Rochester
- University of Birmingham
- Columbia University
- Peking University
- University of Colorado, Denver
- University of Copenhagen
- Medical University of South Carolina
- Icahn School of Medicine at Mount Sinai
- Mesoblast, Inc.
- Government of China
- University of Alabama, Birmingham
- University of Texas, Tyler
- Pulmonary Associates, Phoenix, AZ
- St Joseph's Medical Center, Towson, MD
- Veritas Clinical Specialties, Topeka, KS
- Alpha-1 Foundation
- Stony Wold-Herbert Fund, Inc.
- Syneos Health
- The Cleveland Clinic
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (3)